Several studies strongly support the development of NOTCH1 inhibitors for targeted cancer therapy, particularly for T-ALL, where recurrent NOTCH1 mutations are common and cancer dependency has been well established (16–21). Here, NOTCH1 is linked to acute lymphoblastic leukemia.